Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 562

Results For "LA"

7964 News Found

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
News | October 31, 2022

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.


USFDA issues Form-483 for Lupin's Nagpur Unit-2
Drug Approval | October 31, 2022

USFDA issues Form-483 for Lupin's Nagpur Unit-2

The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US


Zydus receives final approval from USFDA for Acetaminophen injection
Drug Approval | October 30, 2022

Zydus receives final approval from USFDA for Acetaminophen injection

Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data


Kopran acquire assets of Abhinandan Rasayan
News | October 30, 2022

Kopran acquire assets of Abhinandan Rasayan

Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity


Mandaviya addresses Second G20 Health Ministers Meet
News | October 28, 2022

Mandaviya addresses Second G20 Health Ministers Meet

He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods


ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
News | October 28, 2022

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit

It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.


USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
Drug Approval | October 27, 2022

USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

The CRL did not identify any outstanding scientific issues with the product.


Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Clinical Trials | October 27, 2022

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

Results reinforce commitment to next-generation oral SERD development programme


Robert M. Davis is the new Chairman of Merck
People | October 27, 2022

Robert M. Davis is the new Chairman of Merck

Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.